Entera Bio (ENTX)

• Market cap: $125M
• 1 day: 8.33%
• 5 days: 13.28%
• 1 month: 40%
• 3 months: 35.15%
• 6 months: 22.42%
• Year to date: 21.33%
• 1 year: 44.44%
• 5 years: 148.18%
• 10 years: -56.53%
• Sector: Healthcare
• Industry: Biotechnology

About: Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

Employees: 21